Skip to main content
. 2021 Apr 15;23(4):e24153. doi: 10.2196/24153

Table 1.

Demographic and clinical characteristics of our Kaiser Permanente Southern California patient cohort during 2012-2016.

Characteristics Data instances associated with no asthma-related hospital visit in the succeeding year (n=763,837), n (%) Data instances associated with asthma-related hospital visits in the succeeding year (n=18,925), n (%) Data instances (n=782,762), n (%)
Age (years)

≥65 108,662 (14.23) 2288 (12.09) 110,950 (14.17)

18-65 415,889 (54.45) 8557 (45.22) 424,446 (54.22)

6 to <18 188,583 (24.69) 5039 (26.63) 193,622 (24.74)

<6 50,703 (6.64) 3041 (16.07) 53,744 (6.87)
Gender

Female 443,410 (58.05) 10,590 (55.96) 454,000 (58.00)

Male 320,427 (41.95) 8335 (44.04) 328,762 (42.00)
Race

White 477,542 (62.52) 10,040 (53.05) 487,582 (62.29)

Native Hawaiian or other Pacific Islander 7692 (1.01) 230 (1.22) 7922 (1.01)

Black or African American 110,869 (14.51) 4982 (26.33) 115,851 (14.80)

Asian 68,781 (9.00) 1282 (6.77) 70,063 (8.95)

American Indian or Alaska native 3745 (0.49) 86 (0.45) 3831 (0.49)

Unknown or unreported 95,208 (12.46) 2305 (12.18) 97,513 (12.46)
Ethnicity

Non-Hispanic 449,795 (58.89) 10,577 (55.89) 460,372 (58.81)

Hispanic 299,240 (39.18) 8131 (42.96) 307,371 (39.27)

Unknown or unreported 14,802 (1.94) 217 (1.15) 15,019 (1.92)
Insurance

Self-paid plan 104,479 (13.68) 2224 (11.75) 106,703 (13.63)

Public 216,320 (28.32) 7469 (39.47) 223,789 (28.59)

High deductible plan 80,393 (10.52) 1426 (7.54) 81,819 (10.45)

Exchange (also known as marketplace) 39,050 (5.11) 735 (3.88) 39,785 (5.08)

Commercial (employer-paid) 521,101 (68.22) 11,311 (59.77) 532,412 (68.02)

Other 265,264 (34.73) 6064 (32.04) 271,328 (34.66)
Number of years from the first visit related to asthma in the data set

>3 439,930 (57.59) 10,919 (57.70) 450,849 (57.60)

≤3 323,907 (42.41) 8006 (42.30) 331,913 (42.40)
Asthma medication fill

Systemic corticosteroid 236,246 (30.93) 10,837 (57.26) 247,083 (31.57)

Short-acting, inhaled beta-2 agonist 537,442 (70.36) 16,242 (85.82) 553,684 (70.73)

Mast cell stabilizer 20 (0.00) 0 (0.00) 20 (0.00)

Long-acting beta-2 agonist 33,576 (4.40) 1694 (8.95) 35,270 (4.51)

Leukotriene modifier 85,299 (11.17) 4125 (21.80) 89,424 (11.42)

Combination of long-acting beta-2 agonist and inhaled corticosteroid 88,847 (11.63) 3975 (21.00) 92,822 (11.86)

Inhaled corticosteroid 325,156 (42.57) 11,841 (62.57) 336,997 (43.05)
Comorbidity

Sleep apnea 20,465 (2.68) 575 (3.04) 21,040 (2.69)

Sinusitis 112,341 (14.71) 2832 (14.96) 115,173 (14.71)

Premature birth 16,607 (2.17) 690 (3.65) 17,297 (2.21)

Obesity 171,666 (22.47) 4776 (25.24) 176,442 (22.54)

Gastroesophageal reflux 101,180 (13.25) 2778 (14.68) 103,958 (13.28)

Eczema 82,425 (10.79) 2944 (15.56) 85,369 (10.91)

Cystic fibrosis 135 (0.02) 3 (0.02) 138 (0.02)

Chronic obstructive pulmonary disease 27,388 (3.59) 999 (5.28) 28,387 (3.63)

Bronchopulmonary dysplasia 241 (0.03) 22 (0.12) 263 (0.03)

Anxiety or depression 160,719 (21.04) 4231 (22.36) 164,950 (21.07)

Allergic rhinitis 164,036 (21.48) 4673 (24.69) 168,709 (21.55)
Smoking status

Never smoker or unknown 477,263 (62.48) 11,885 (62.80) 489,148 (62.49)

Former smoker 133,456 (17.47) 2870 (15.17) 136,326 (17.42)

Current smoker 153,118 (20.05) 4170 (22.03) 157,288 (20.09)